Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1b crossover study of TAK-925 in idiopathic hypersomnia
jRCT2080224996Phase 1Completed
- Sponsor
- Takeda
- Start
- Dec 2019
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, double-blind trial of danavorexton in hypersomnolence disorder (2 arms), sponsored by Takeda. Primary endpoint: Safety and tolerability of single 9-hour IV infusion of TAK-925 112 mg. Started Dec 2019; status: completed.
02
Drugs
danavorexton
03
Conditions
hypersomnolence disorder
Beyond the preview
Go deeper on jRCT2080224996.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224996.